Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Core Insights - The FDA has approved Dupixent (dupilumab) for the treatment of allergic fungal rhinosinusitis (AFRS) in patients aged 6 years and older, marking it as the first specific treatment for this condition [1][2][6] - Dupixent has shown significant efficacy in reducing nasal symptoms and the need for surgery or systemic corticosteroids, establishing a new standard of care for AFRS [3][10] - The approval is based on the LIBERTY-AFRS-AIMS Phase 3 trial, which demonstrated a 50% improvement in sinus opacification scores for Dupixent compared to 10% for placebo at Week 52 [3][8] Company Overview - Regeneron Pharmaceuticals, Inc. and Sanofi jointly developed Dupixent, which is now approved for nine distinct diseases driven by type 2 inflammation [1][13] - The companies are committed to expanding access to Dupixent globally, with plans for additional regulatory submissions in other countries [6][12] - Regeneron utilizes its proprietary VelocImmune technology to develop fully human monoclonal antibodies, including Dupixent [10][14] Clinical Trial Results - The LIBERTY-AFRS-AIMS trial included 62 participants, showing Dupixent significantly improved sinus opacification scores and nasal congestion [3][7] - Secondary endpoints indicated a 67% improvement in patient-reported nasal congestion at Week 24, increasing to 81% at Week 52 [4][10] - Dupixent also reduced the risk of systemic corticosteroid use and surgery by 92% over 52 weeks [10] Safety Profile - The safety profile of Dupixent in the LIBERTY-AFRS-AIMS trial was consistent with its known profile in chronic rhinosinusitis with nasal polyps [5][10] - Common adverse reactions included injection site reactions, conjunctivitis, and arthralgia, occurring in more than 1% of patients [5][10] Market Potential - Dupixent is currently being used by over 1.4 million patients globally, indicating strong market acceptance and potential for further growth [13] - The approval for AFRS adds to Dupixent's existing indications, enhancing its position in the treatment landscape for chronic type 2 inflammatory diseases [1][3]